In a report released today, Jack Slevin from Jefferies maintained a Hold rating on Agilon Health, with a price target of $1.10.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Jack Slevin has given his Hold rating due to a combination of factors affecting Agilon Health. The company is currently facing significant challenges, including leadership changes and ongoing issues with prior-period development, which have impacted their financial performance. The recent departure of the CEO and the interim leadership by Ron Williams highlight a sense of urgency to address these problems.
Despite these challenges, Agilon Health has a cash balance that provides some runway to navigate these issues, but the margin for error is narrowing. The company’s valuation and cash situation suggest that management might need to explore aggressive options to stabilize performance. Slevin remains cautious and recommends holding the stock until a clearer strategic direction is established, with a price target set at $1.10.